Pathogenesis, prevention, and treatment of diabetic nephropathy

被引:417
作者
Cooper, ME [1 ]
机构
[1] Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Heidelberg West, Vic 3081, Australia
关键词
D O I
10.1016/S0140-6736(98)01346-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is likely that the pathophysiology of diabetic nephropathy involves an interaction of metabolic and haemodynamic factors. Relevant metabolic factors include glucose-dependent pathways such as advanced glycation, increased formation of polyols, and activation of the enzyme, protein kinase C. Specific inhibitors of the various pathways are now available, enabling investigation of the role of these processes in the pathogenesis of diabetic nephropathy and potentially to provide new therapeutic approaches for the prevention and treatment of diabetic nephropathy. Haemodynamic factors to consider include systemic hypertension, intraglomerular hypertension, and the role of vasoactive hormones, such as angiotensin II. The mainstay of therapy remains attaining optimum glycaemic control. Antihypertensive therapy has a major role in slowing the progression of diabetic nephropathy. Agents that interrupt the renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists may be particularly useful as renoprotective agents in both the hypertensive and normotensive context.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 88 条
  • [41] KELLY DJ, IN PRESS KIDNEY INT
  • [42] Kimmelstiel P, 1936, AM J PATHOL, V12, P83
  • [43] GLYCOSYLATED HEMOGLOBIN AND THE RISK OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS
    KROLEWSKI, AS
    LAFFEL, LMB
    KROLEWSKI, M
    QUINN, M
    WARRAM, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (19) : 1251 - 1255
  • [44] CAPTOPRIL OR CONVENTIONAL THERAPY IN HYPERTENSIVE TYPE-II DIABETICS - 3-YEAR ANALYSIS
    LACOURCIERE, Y
    NADEAU, A
    POIRIER, L
    TANCREDE, G
    [J]. HYPERTENSION, 1993, 21 (06) : 786 - 794
  • [45] Lewis, 1997, NEPHROLOGY S1, V3, P1222
  • [46] THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY
    LEWIS, EJ
    HUNSICKER, LG
    BAIN, RP
    ROHDE, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) : 1456 - 1462
  • [47] REACTIVE GLYCOSYLATION ENDPRODUCTS IN DIABETIC UREMIA AND TREATMENT OF RENAL-FAILURE
    MAKITA, Z
    BUCALA, R
    RAYFIELD, EJ
    FRIEDMAN, EA
    KAUFMAN, AM
    KORBET, SM
    BARTH, RH
    WINSTON, JA
    FUH, H
    MANOGUE, KR
    CERAMI, A
    VLASSARA, H
    [J]. LANCET, 1994, 343 (8912) : 1519 - 1522
  • [48] Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes
    Marre, M
    Jeunemaitre, X
    Gallois, Y
    Rodier, M
    Chatellier, G
    Sert, C
    Dusselier, L
    Kahal, Z
    Chaillous, L
    Halimi, S
    Muller, A
    Sackmann, H
    Bauduceau, B
    Bled, F
    Passa, P
    AlhencGelas, F
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) : 1585 - 1595
  • [49] MATHIESEN ER, 1995, DIABETOLOGIA, V38, pA46
  • [50] How to protect the kidney in diabetic patients - With special reference to IDDM
    Mogensen, CE
    [J]. DIABETES, 1997, 46 : S104 - S111